Tilray CEO on first earnings file and rising cannabis substitute
Tilray CEO Brendan Kennedy discusses his firm’s enhance alongside the expansion of the clinical pot substitute as a total.
Read more » 
Tilray CEO Brendan Kennedy discusses his firm’s enhance alongside the expansion of the clinical pot substitute as a total.
Read more »